title: Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.
abstract: BACKGROUND
  Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches.
  
  
  METHODS
  A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.
  
  
  CONCLUSIONS
  Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.
authors.affiliation: Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 262, Orange CA 92868, USA.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
authors.forename: David C
authors.initials: DC
authors.lastname: Choi
authors.forename: Gordon
authors.initials: G
authors.lastname: Pugmire
authors.forename: Robert A
authors.initials: RA
authors.lastname: Burger
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab